Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Menen – page 40

1 845 clinical trials in Menen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Menen at a glance
1 845
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 845 trials in Menen

Open in trial search

Study on Intra-Arterial Thrombolysis with Alteplase for Patients with Acute Ischemic Stroke in the Anterior Circulation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:CHRU De Nancy

Dermatomyositis

Recruiting

Study on Baricitinib for Patients with Relapsing or Naïve Dermatomyositis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Baricitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

B-cell lymphoma+1

Recruiting

Study of valemetostat tosylate tablets in patients with relapsed or refractory B-cell lymphoma, including aggressive B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Hodgkin lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:LYSARC

Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Centre Hospitalier De Versailles

Study on Stopping Dasatinib in Patients with Chronic Myeloid Leukemia After a Previous Attempt to Stop Treatment

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dasatinib
  • Sponsor:Region Uppsala

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Placenta praevia+1

Recruiting

Study on Tranexamic Acid to Prevent Blood Loss in Women with Placenta Previa Undergoing Cesarean Delivery

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Potassium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study of Intrapleural Photodynamic Therapy with Aminolevulinic Acid Hydrochloride and Nivolumab for Patients with Malignant Pleural Mesothelioma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Study on the Use of Methyl Aminolevulinate and PAGETEX Device for Treating Vulvar Extra-Mammary Paget's Disease in Women

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl Aminolevulinate
  • Sponsor:Centre Hospitalier Universitaire De Lille

Study on Adjusting Adalimumab Dosage for Patients with Rheumatoid Arthritis in Remission

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Centre Hospitalier Universitaire De Saint Etienne

Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Celgene Corp.

Study Comparing mFOLFIRINOX and Capecitabine or Gemcitabine for Patients with Resected Ampullary Adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Menen

What the registry says about research in the country

01 Advanced Lung Cancer Research

Investigating innovative treatments for Non-Small Cell Lung Cancer (NSCLC), with a focus on patients carrying specific genetic mutations like EGFR Exon 20 insertions. The research evaluates combination therapies using zipalertinib with traditional chemotherapy to improve treatment outcomes.

  • Targeted Therapy Development
  • Genetic Mutation Analysis
  • Combination Treatment Strategies

Studies aim to determine optimal dosing and measure progression-free survival rates in advanced cases.

02 Immunotherapy Research

Evaluating the effectiveness of therapeutic cancer vaccines compared to conventional chemotherapy in treating metastatic NSCLC patients. The research specifically focuses on patients with HLA-A2 positive phenotype who have experienced immunotherapy failure.

  • Cancer Vaccine Development
  • Treatment Resistance Studies
  • Overall Survival Analysis

Research aims to demonstrate improved survival outcomes using novel vaccine-based approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.